NEW YORK (GenomeWeb News) - Complete Genomics will sequence glioblastoma and melanoma samples for the Broad Institute as part of a pilot study the company announced last month.
For the project, Complete Genomics will use its DNA sequencing technology to sequence five samples provided by the Broad Institute. The first genome will be a sample that has already been studied extensively by the scientific community. The other four genomes will include glioblastoma and melanoma samples and their matched normal controls.
"Our newly-released, proof-of-concept sequencing data have been well received by the scientific community and we are now looking forward to demonstrating our technology's potential to reveal new avenues of medical research," Complete Genomics Chairman, President, and CEO Clifford Reid said in a statement.